Immuneering Corporation
IMRX
$1.27
$0.021.60%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -4.07% | 1.74% | 1.06% | 1.90% | 7.44% |
| Depreciation & Amortization | 0.00% | 0.00% | 0.00% | 0.00% | -2.67% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.69% | 10.19% | 9.15% | 10.12% | 12.20% |
| Operating Income | -9.69% | -10.20% | -9.23% | -10.39% | -12.89% |
| Income Before Tax | -14.15% | -12.46% | -8.06% | -5.77% | -5.86% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -14.15% | -12.46% | -8.06% | -5.77% | -5.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.15% | -12.46% | -8.06% | -5.77% | -5.86% |
| EBIT | -9.69% | -10.20% | -9.23% | -10.39% | -12.89% |
| EBITDA | -9.69% | -10.17% | -9.20% | -10.34% | -12.81% |
| EPS Basic | -7.79% | -5.05% | 1.06% | 4.19% | 1.50% |
| Normalized Basic EPS | -6.98% | -3.92% | 0.63% | 3.74% | 0.41% |
| EPS Diluted | -7.79% | -5.05% | 1.06% | 4.19% | 1.50% |
| Normalized Diluted EPS | -6.98% | -3.92% | 0.63% | 3.74% | 0.41% |
| Average Basic Shares Outstanding | 5.54% | 6.66% | 8.96% | 10.34% | 7.65% |
| Average Diluted Shares Outstanding | 5.54% | 6.66% | 8.96% | 10.34% | 7.65% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |